Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most.
Saved in:
| Title: | Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most. |
|---|---|
| Authors: | Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Sørensen JB; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. |
| Source: | Translational lung cancer research [Transl Lung Cancer Res] 2025 Feb 28; Vol. 14 (2), pp. 310-313. Date of Electronic Publication: 2025 Feb 21. |
| Publication Type: | Editorial; Comment |
| Journal Info: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2218-6751 |
|---|---|
| DOI: | 10.21037/tlcr-24-961 |
